New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
08:04 EDTCYTXCytori says study using therapy to treat ACL injury underway in Spain
Cytori Therapeutics announces the first investigator-initiated study evaluating Cytori Cell Therapy as a potential concomitant treatment for Anterior-cruciate ligament injury. The study is led by Ramon Cugat, M.D. PhD. Dr. Cugat is President of the Medical Council for the Catalan Soccer Delegation's Health Insurance Company under the Spanish Soccer Federation, President of the Board of Directors of the Council of the Garcia Cugat Foundation for Regenerative Medicine Research, Professor of the Chair of the Garcia Cugat Foundation at CEU Cardenal Herrera University, Director of the Orthopaedic Surgical Department in Hospital Quiron, Barcelona, Spain and Head of Trauma and Orthopaedic Surgery in Mutua Patronal Montañesa. The study is an investigator-initiated study to determine the feasibility of using Cytori Cell Therapy on patients undergoing complete ACL reconstruction. The study is approved to treat 20 patients who will be followed by both clinical and imaging end points. Thirteen patients have been treated thus far, full enrollment is expected this year and data is being evaluated on a rolling basis. The study was initiated in 2013 under an approval from the Spain Ministry of Health, Social Services and Equality. It was organized by a multidisciplinary team of researchers at Hospital Quiron.
News For CYTX From The Last 14 Days
Check below for free stories on CYTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
08:12 EDTCYTXCytori sees 'modest overall revenue growth' in FY14
The company said, "Despite the impact of the cost reduction efforts, Cytori continues to anticipate modest overall revenue growth in 2014. Overall revenue growth in 2015 and 2016 will likely continue to be modest but should show a positive contribution margin beginning in 2015 based on the combination of recent expense reductions and forecasted increases in sales to Lorem Vascular and other partners, as well as through Cytori’s leaner direct sales teams in both Japan and Europe." FY14 revenue consensus $15.06M.
08:05 EDTCYTXCytori announces restructuring, cost reduction plans
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use